Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Immune checkpoint inhibitors (ICIs) have shown significant therapeutic effects in the treatment of small-cell-lung cancer (SCLC).
Clinical trials have evaluated the efficacy of ICIs, such as PD-1 inhibitors (e.g., pembrolizumab and nivolumab), as first-line therapy for Small-Cell-Lung-Cancer (SCLC).
A systematic review and meta-analysis of 16 relevant clinical trials comprising 4,476 patients found that ICIs as first-line therapy conferred a statistically significant benefit in overall survival.
He & Hu 2023 Front Immunol.14: 112…